FAERSFGFR

Ping Li1, Liming Wu2, Zhihui Song3

  • 1Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Scientific reports
|July 18, 2025
PubMed
概括

现实世界的数据揭示了纤维细胞生长因子受体氨酸激酶抑制剂 (FGFR-TKIs) 的新安全问题,如herdafitinib,pemigatinib和futibatinib. 这项分析突出了特定患者群体中以前未被识别的不良事件和风险.